Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of CaliforniafiledCriticalThe Regents Of The University Of California
Publication of HK1166270ApublicationCriticalpatent/HK1166270A/en
The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis.
HK12106985.0A2009-07-242010-07-26Methods and compositions for treating and preventing disease associated with avb5 integrin
HK1166270A
(en)
Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
Antibody, a hybridoma for producing the antibody, a conjugate comprising the antibody, a pharmaceutical composition comprising the antibody and/or the conjugate and uses thereof
Monoclonal antibody or fragment thereof which binds full length human lif, pharmaceutical composition comprising the same and process for its preparation
Antibody, a hybridoma for producing the antibody, a conjugate comprising the antibody, a pharmaceutical composition comprising the antibody and/or the conjugate and uses thereof